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Reduction of plasma apolipoprotein-B by effective removal of circulat-
ing glycation derivatives in uremia. Patients with diabetes and renal
insufficiency (Db/ESRD), a group subject to accelerated atherosclerosis
exhibit marked increases in the levels of circulating, glycation-derived
reactive substances, termed advanced glycation endproducts (AGEs).
These products have been previously shown to react covalently with
apoliprotein B (ApoB) to form AGE-ApoB, a modification that results in
delayed low density lipoprotein (LDL) clearance and possibly to dyslipi-
demia. Because the effect of hemodialysis on AGE removal was shown to
be unsatisfactory, based on single intradialytic studies, we examined the
effect of long-term hemodialysis therapy on serum AGE-ApoB levels, as
well as on total serum ApoB of 25 DbIESRD patients treated by two types
of hemodialysis filters, the Fresenius Inc. F8, as the low flux (LF), or
high-flux polysulfone AN69 (HF) for two months using an AGE-specific
ELISA. At the end of eight weeks, circulating AGE-ApoB levels were
reduced significantly (by 35%) from baseline (P = 0.039) in patients
treated by HF compared to a modest 16% reduction noted in patients
treated by LF (P 0.05) N = 12, P = 0.047). Of note, total plasma ApoB
was reduced by 27% from baseline (P = 0.02) in patients treated by HF
compared to a 6% reduction noted in those treated with LF (P 0.8). In
vitro comparison of AGE mass balance, and mass adsorption by the
different filters revealed that the higher efficiency of HF filter was due to
greater adsorption. The association of reduced AGE-ApoB levels with a
decrease in total circulating ApoB by HF and not by LF dialysis suggests:
(1) a causal link between AGE clearance and dyslipidemia in diabetic
ESRD, and, (2) that more efficient modes of renal replacement treatment
and AGE removal could significantly benefit clinical outcome.
Fifty percent of diabetic patients die within two years of starting
hemodialysis, with cardiovascular disease consistently being the
leading cause of death [1]. A factor that may contribute to the
progressive burden of atherosclerotic disease in this population is
dyslipidemia. One lipoprotein frequently implicated in the patho-
genesis of atherosclerosis is low density lipoprotein (LDL) [2—4].
In diabetic hemodialysis patients, the structure and function of
LDL may be altered, leading to impaired metabolism, and
increased atherogenic potential [5, 6].
Low density Jipoprotein consists of a core composed almost
entirely of cholesterol esters, and an outer coat consisting of
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phospholipids and primarily one apoprotein, apoprotein B100
(ApoB) [7, 8]. Eighty percent of plasma LDL is cleared from the
circulation by the LDL receptor pathway [9]. Alterations in the
structure of the lipid or protein moieties of LDL may hinder
effective clearance by the LDL receptor, leading to its accumula-
tion in plasma and tissue. There is recent evidence that both the
lipid and apoprotein portions of LDL in diabetics with end-stage
renal disease may be modified by advanced glycation end-prod-
ucts (AGEs) in a manner that delays its receptor mediated
clearance [5]. Both diabetic and nondiabetic patients with end-
stage renal disease have been found to have high serum and tissue
levels of AGEs [101. AGEs are formed in a series of reactions
initiated by the nonenzymatic attachment of glucose to the amino
groups of proteins. Several rearrangements then lead to the
production of AGEs, which are irreversibly bound to proteins.
During the normal turnover of tissue components, AGE-protein
degradation products enter the circulation primarily as low mo-
lecular weight AGE-rich peptides, and are excreted in the urine
[10, 15]. Serum levels of these AGE-peptides are inversely related
to creatinine clearance, reaching very high levels in end-stage
renal disease [10, 15]. The heterogeneous AGE-peptides isolated
from human serum have been shown to include reactive species
which can crosslink rapidly with LDL to form AGE-ApoB and
AGE-lipid [5, 151, thus raising the plasma level of modified LDL
independent of glucose levels. Injection of AGE-modified human
LDL into transgenic mice expressing the human LDL receptor
revealed markedly impaired clearance kinetics [5]. Considered
together, these data suggest that circulating AGE-peptides can
modify native LDL in a manner that inhibits its normal metabo-
lism.
Modified LDL is deposited within the vascular wall and is
eventually removed via macrophage scavenger receptors leading
to the formation of foam cells, a classic feature of the atheroscle-
rotic lesion [14]. In diabetic hemodialysis patients already suffer-
ing from atherosclerosis and markedly elevated AGE ApoB-LDL,
this mechanism may have a major impact on the rate of progres-
sion and associated cardiovascular risk.
The above considerations suggest that it may be clinically
beneficial to attempt to lower circulating serum AGE-peptide
levels in diabetic hemodialysis patients. Studies of individual
dialysis treatments suggest that AGE-peptides may be better
cleared from the circulation by high-flux than by low flux hemo-
dialysis [15]. Such improved clearance may be attained by diffu-
sion, convection or membrane adsorption. Larger molecules such
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F60 (in vitro study
F8 AN69 (Filtral 16) only)
Polysulfone Polyacrylonitrile
1.8 1.7
Membrane Polysulfone
Surface area 1.2
KUF mt/hr/mm Hg 8.1 44.1 40
KOA urea ml/min 801 626 757
Abbreviations are: KUF, ultrafiltration coefficient; KOA, overall activ-
ity coefficient.
as AGE-peptides (molecular weight range 2,000 to 6,000 daltons)
are cleared poorly by diffusion [10, 15]. The relative importance of
convective or adsorptive clearance increases as a function of
molecular weight, and this may underlie the mechanism of
improved clearance by high flux filters [16]. In this report, we
examined the effect of chronic high-flux dialysis on AGE-peptide
clearance, and the corresponding changes of the serum levels of
glycated and total ApoB in a randomized, prospective fashion. In
addition, we performed in vitro studies on the mechanisms of
AGE clearance by low and high flux dialyzers.
METHODS
Clinical study
The purpose of this study was to determine the long term effect
of high-flux hemodialysis on plasma AGE-peptides and related
AGE-ApoB and total ApoB in patients with end-stage renal
disease.
Patient population and study design
Among the Winthrop-University Hospital Dialysis Center pa-
tient population, diabetic hemodialysis patients dialyzed for at
least six months were selected for study. Exclusion criteria in-
cluded lack of a stable dialysis access, urea reduction ratio (URR)
<60%, hospitalization within one month for marked changes in
metabolic control, and concomitant treatment with an angiotensin
converting enzyme inhibitor or lipid lowering medications. Thirty
patients consented to participate in the study. All patients were
dialyzed chronically with a low-flux polysulfone F8 dialysis filter
(Fresenius Inc., Germany) (Table 1). Patients were randomly
assigned to one of two groups. Sixteen patients were changed to a
high-flux AN69 Filtral 16 dialyzer (Hospal Inc., Lyon, France) for
a period of two months (high-flux group). Fourteen patients
remained on an F8 dialyzer (low flux group) for the two month
study period. There were five patient withdrawals during the study
period, two in the high-flux group, and three in the low flux group.
All dialysis treatments used unfractionated heparin for anticoag-
ulation. Prescribed dialysis time ranged from 2.75 to 4.25 hours,
and no changes were made during the study period. Dietary
prescription was comprised of 1.0 to 1.2 glkg body wt/day of
protein, 30% of caloric intake as fat, and 50 to 55% of caloric
intake as carbohydrates. Blood samples for determination of
serum AGE-peptides, apoprotein B and glycated ApoB were
collected at baseline and at the end of the two month study period.
Samples were collected from the vascular access both before and
after dialysis, and were immediately placed on ice. All samples
were centrifuged (5,000 rpm for 10 mm) within 60 minutes of
collection, and were stored at —70°C until assayed. Other labo-
ratory testing included weekly plasma glucose and baseline, and
two months hemoglobin Ale. Dialysis efficiency for small solute
clearance was determined by the urea reduction ratio [(predialysis
BUN — post-dialysis BUN)/predialysis BUN x 100].
Total serum AGE-protein and AGE-ApoB levels were moni-
tored by a competitive AGE-specific ELISA [17], as described,
and AGE-ApoB was measured by a sandwich AGE-ELISA, using
an anti-AGE monoclonal antibody (4G9), kindly provided by
Alteon Inc. (Ramsey, NJ, USA), immobilized on microtiter plates
and a polyclonal anti-ApoB-HRP conjugated antibody (Biode-
sign, Kennebunkport, ME, USA) (1:500). Briefly, wells were
coated with 4G9 (1.5 jig/well), followed by the addition of serum
(100 jil), 0.9 ml PEG (6.66%) (Sigma), and 100 jil SDS (0.05% in
PBS) for 10 hours at 28°C, after which anti-ApoB-HRP (100 jid)
was added for one hour at 37°C prior to reading OD at 450 nm.
Total serum ApoB was determined by the Incstar SPQ Test
System (Incstar Corp., Stillwater, MN, USA) [18].
In vitro dialyzer studies
The purpose of this portion of the study was to (1) compare the
in vitro clearance of AGE-peptides by low flux versus high-flux
dialyzers, (2) to compare AGE-peptide clearance by polysulfone
to that by polyacrylonitrile membranes, and (3) to determine the
proportion of AGE-peptide clearance due to membrane adsorp-
tion. Three types of dialysis filters were studied, one low flux
polysulfone (F8, Fresenius Inc.) and two high-flux, polysulfone
(F60, Fresenius Inc.) and polyacrylonitrile (AN69 Filtral 16,
Hospal Inc.). Specifications of the dialyzers are listed in Table 1.
The in vitro test solution consisted of pooled human uremic
serum (containing —90 AGE U/mI), further enriched in AGE by
adding AGE-HSA peptides (67 AGE U/mg) (1:1 vol/vol). AGE-
HSA peptides were generated by incubating human serum albu-
min (50 mg/mI) in 0.5 M glucose for six weeks, as previously
described [17], followed by enzymatic digestion with proteinase-K
(1% wt/wt) at 37°C for 16 hours and heat-inactivation at 65°C for
one hour. AGE concentration in the final solution was over 1,000
AGE U/ml, (> 10-fold above that in uremic serum), consisting
largely of < 6.0 kDa peptides. A single pass circuit was con-
structed consisting of arterial, venous, and dialysate reservoirs
connected to a Cobe C3 hemodialysis machine. Each experiment
lasted 30 minutes, during which samples were collected from the
reservoirs every 10 minutes. After priming the cirquit, the AGE
test solution was perfused at a rate of 200 ml/min. Bicarbonate
dialysate solution ran in a countercurrent direction at a rate of 300
ml/min. Three perfusion studies were conducted per dialyzer.
Mass balance of AGE-peptide was determined as: mass = con-
centration (AGE U/mI) X volume. The percent mass adsorbed at
any point in time was calculated against the baseline AGE-peptide
(total) concentration: mass adsorbed = 100 (arterial reservoir
percent mass + venous reservoir percent mass + dialysate
reservoir percent mass).
Statistical analyses
All results are expressed as mean sn. Student's t-tcst was used
for comparisons between low flux and high flux dialysis. Two way
ANOVA was used for comparisons between the three dialyzers
studied in the in vitro studies. The AGE-peptide reduction ratio
was calculated as (predialysis AGE-peptide level — post-dialysis
AGE peptide level)/predialysis AGE-peptide level X 100. P
values < 0.05 were considered statistically significant.
Table 1. Dialyzer characteristics
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Table 2. Baseline population characteristics
Patients High-flux Low-flux
N 13 12
Age years 55.0 5.0 54.0 5.0
Gender, M:F 8:5 6:6
Months on dialysis 17.4 4.0 18.0 4.0
Urea reduction ratio baseline 67.0 4.0 68.0 4.0
Serum AGE-peptides U/mi 65.0 24.0 60.0 16.0
Hemoglobin A1C % 11.0 1.0 10.0 1.0
Serum cholesterol mg/dl 232.0 23.0 233.0 24.0
Triglycerides mg/dl 151.0 18.0 151.0 13.0
RESULTS
Patient study
There was no significant difference between the groups at
baseline with respect to age, sex, duration of dialysis, urea
reduction ratio, serum AGE-peptides, or diabetic control based
on HgAlc, serum cholesterol or triglycerides (Table 2). In all
patients ESRD was attributed to diabetic nephropathy. After the
two-month study period, there were no significant differences in
the urea reduction ratio (68 4% low flux, 67 4% high-flux,
P = NS) between the two groups, or in the adequacy of glucose
control (HgAlc, 10.3 1.9 low flux, 11.0 1.0, high-flux, P =
NS).
After two months of treatment with high-flux dialysis, steady-
state serum AGE peptide levels were not significantly changed
from baseline. In contrast, serum AGE peptide levels had in-
creased significantly over this time period in patients treated with
low flux hemodialysis (Fig. 1). At the completion of the study
period, predialysis serum AGE peptide levels were significantly
lower among patients treated with high flux compared to low flux
hemodialysis (71.0 25.6 U/ml compared to 102.6 29.2 U/mI,
respectively, P = 0.005).
Over the same period of time of treatment with high flux
dialysis, circulating AGE-ApoB levels decreased by 35% (P =
0.039; Fig. 2). A smaller, though statistically significant decrease in
AGE-ApoB was also noted in the low flux dialysis group. In the
low flux dialysis group, serum AGE-ApoB decreased only by 15%
from baseline (P = 0.047) (Fig. 2), yielding a significant difference
between the two groups (P = 0.035). Notably, during this time
interval on high flux dialysis, total serum ApoB decreased by 27%
from 72 25 mg/dl (baseline) to 49 18 mg/dl at two months,
P = 0.02 (Fig. 3), whereas in the low flux dialysis group, serum
ApoB remained unchanged, (baseline 63 19 mg/dl, 61 17
mg/dl at 2 months, P = NS; Fig. 3).
In vitro study
High flux dialyzers exhibited a greater total AGE-peptide mass
clearance than the low flux dialyzer, F60 versus F8, P < 0.05;
AN69 versus F8, P < 0.01; for AN69 versus F60, P = NS (Table
3a). In addition, the AGE-peptide mass appearance in the
dialysate reservoir (indicative of convective and diffusive clear-
ance) was greater in the high flux dialyzers (F60 vs. F8, P < 0.05;
AN69 vs. F8, P < 0.05; and AN69 vs. F60, P = NS). The
proportional adsorptive clearance was also higher in the high flux
dialyzers (F60 vs. F8, P = 0.05; AN69 vs. F8, P < 0.05; and AN69
vs. F60, P = 0.07). The adsorptive clearance among all dialyzers
was greatest during the first 10 minutes of study (38.0 2.6% of
Fig. 1. Steady-state serum AGE-peptide levels in diabetic patients with
end-stage renal disease (ESRD) treated with high flux hemodialysis
(AN69) are kept constant, while those treated with low flux (F8) continue
to rise over time. Data are expressed as the mean so of AGE U/mI,
determined by ELISA. *F8 baseline versus two months, P = 0.0005;
5AN69 versus F8 at two months, P = 0.005.
total membrane adsorption) after which time the rate of clearance
decreased (36.0 3.3% in the next 10 mm, 26.0 3.0% in the
third 10 mm interval; P not significant between the specific
dialyzers; Table 3b).
DISCUSSION
Diabetic patients with end-stage renal disease treated with
hemodialysis have markedly elevated tissue and serum levels of
advanced glycation end-products (AGEs) [10, 15]. These prod-
ucts, which include reactive crosslinking derivatives, form via a
series of nonenzymatic chemical rearrangements leading to per-
manent modification of protein structure and function [12—14]. As
a result, a wide array of potentially pathologic responses are
elicited, including chemical protein-to-protein crosslinking, or
functional alterations, such as increased vascular permeability,
nitric oxide unresponsiveness, procoagulant activity, proliferative
effects, and cytokine and growth factor induction [12—14]. Tissue
or serum AGE components are partially degraded by either local
proteolytic enzymes, or via specific AGE-receptors [12—14]. The
cleavage products that are generated are called AGE-peptides
and circulate in plasma in concentrations inversely related to
creatinine clearance, reaching exceedingly high levels in end-stage
renal disease [10, 15].
Diabetic hemodialysis patients have a 50% risk of mortality
during their first two years on dialysis, with cardiovascular disease
accounting for the greatest proportion of attributable risk [1]. The
dyslipidemia of uremia is thought to be mediated by a number of
mechanisms including increased oxidative modification [19, 20]
and glycation of LDL [6, 21], however, no major contributor to
this process has clearly emerged. Recent in vitro evidence has
AG
E-
Ap
oB
, U
 A
G
E/
m
g 
Ap
of
i 
N
) 
TO
 
N
) 
N
) 
0 
o
 
o
 
N
J 
a
 
a
, 
o
 
0 
0 
0 
0 
0 
N
) 
0 0 
0 
0 
Se
ru
m
 A
po
B,
 m
g/
dI
 
N
) 
o
 
a 
cji
 
o
yo
 
0 0 
(0 0\
 
1648 Fishbane et a!: AGE clearance and dyslipidemia in diabetes
Fig. 2. Steady-state serum AGE.ApoB levels in diabetic patients with
end-stage renal disease (ESRD) treated with high flux (AN69) and low
flux (F8) hemodialysis, at baseline and at two months. Data are expressed
as the mean SD of AGE U/mg serum ApoB, determined by ELISA and
as described in the Methods section. AN69, baseline versus two months,
P = 0.039; *F8, baseline versus two months, P = 0.047.
indicated that circulating AGE-containing substances isolated
from diabetic patients include reactive glycation intermediates
that can crosslink covalently with plasma proteins, such as ApoB
[5, 15]. This ApoB cross-linking by serum AGE-peptides is
prevented by the AGE inhibitor, aminoguanidine, in vitro [5, 15].
In connection with these findings, diabetics with renal failure were
found to have high serum levels of AGE-ApoB, a modification of
ApoB which results in impaired clearance kinetics by the human
LDL receptor [5]. In the diabetic hemodialysis patient, this could
contribute to the dyslipidemic state and cardiovascular risk [1, 19,
20]. More interestingly, a similar rise in AGE-ApoB is exhibited
by non-diabetic patients with end-stage renal disease, attributable
only to increased serum AGE-peptide concentrations, since they
are normoglycemic [5].
Based on the mounting evidence on the atherogenic potential
of AGEs, recently supported by animal studies infused with
exogenously AGE-modified albumin [22, 23], it follows that
therapeutic measures which could lower these serum-AGE levels
would be beneficial. Normally, low molecular weight AGE-pep-
tides (2 to 10 kDa) are cleared from the circulation by the kidneys,
thus, their concentration in plasma is inversely correlated with
creatinine clearance [10, 15]. Recent evidence suggests that
various dialytic modalities including low flux and high-flux hemo-
dialysis, and peritoneal dialysis do not differ significantly in their
effectiveness for clearing AGE-peptides [10, 15, 24]. However,
based on more detailed analysis of AGE-peptide kinetics during a
single dialysis session, a polysulfone high flux dialyzer resulted in
a 48% reduction, although AGE-peptides returned to predialysis
levels within a short period of time [15]. This suggested that
although high flux dialysis had the potential for more efficiently
removing these substances, other factors regarding its application
Fig. 3. Serum ApoB levels in diabetic patients with end-stage renal
disease (ESRD), treated with high flux (AN69) and low flux (F8)
hemodialysis, at baseline and at two months. Data are expressed as
mean SD of total serum ApoB mg/dl, determined by the Incstar SPQ
Test System. 5AN69, baseline versus two months, P = 0.02.
Table 3a AGE mass appearance %
Dialyzer Dialysate Adsorption Total mass cleared
F8
F60
AN69
7.0 1.Oa 10.0 2.Oa 17.0 3.0
10.0 1.0 20.0 2.0 30.0 3.0
10.0 1.0 28.0 3.0 38.0 3.0
Table 3b. Proportional adsorptive clearance %
10 Mm. 38.0 2.6
20 Mm. 36.0 3.3
30 Mm. 26.0 3.0
up value <0.05 F8 vs. others
needed to be evaluated. The purpose of the current study was to
determine: (a) the long-term effect of each treatment, and, (h)
whether conversion of patients from low flux to high flux dialysis
would alter serum AGE-peptide, AGE-ApoB and total ApoB
levels.
The definition of high flux dialyzer properties varies in the
nephrological literature. The term high flux refers, among other
definitions, to improved clearance of middle molecules compared
to low flux hemodialysis filters. Based on the ongoing National
Institute of Health Hemodialysis Study this is defined as more
effective clearance of beta-2 microglobulin (molecular wt 11.9
kDa) [25]. Improved clearance of middle molecules can be
achieved by diffusion, convection or membrane adsorption. Be-
cause of the wide range of size and charge of the AGE-molecules,
it is likely that much of the clearance is achieved by adsorption.
Consistent with this idea, our in vitro study showed that the
clearance of the AGE-peptides by both the polysulfonc F60
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dialyzer, and the polyacrylonitrile AN69 dialyzer was achieved
mostly by membrane adsorption.
Over the two months of study, serum AGE-peptide levels
remained at baseline in patients placed on the high-flux AN69
dialyzer, compared to those kept on low flux dialysis, in whom the
relative increase of AGE levels over time was significantly greater
and possibly accelerating in a non-linear fashion, presumably due
to the less effective clearance of the latter. This was confirmed by
a higher dialytic AGE-peptide reduction ratio for the AN69
Filtral 16 dialyzer (72% vs. 54%, respectively, P < 0.05), com-
pared to the low flux F8 dialyzer over a two-month period. This
effect was probably due to the high flux properties of the AN69
relative to the F8 dialyzer. There was no significant difference
between the two high-flux dialyzers used in the in vitro study,
suggesting that improved AGE-peptide clearance with the high-
flux dialyzers was due to their high-flux properties per Se, rather
than differences in membrane composition or relative biocompat-
ibility. Adsorption of AGE-peptides to the dialyzer membrane
was the major mode of clearance with all three dialyzers, but this
contribution was most significant in the high-flux dialyzers. It is of
interest that the rate of membrane adsorption for all dialyzers
reached an early plateau as a function of time, most likely
indicative of rapid surface saturation.
The abnormally elevated serum AGE-ApoB levels were re-
duced significantly by chronic treatment with the high flux dia-
lyzer, as were levels of total plasma ApoB. A reduction of
triglycerides has already been noted by several investigators [16,
26—28] although the exact mechanism of beneficial effect of high
flux dialyzer is unknown. Among others, this effect could theoret-
ically also be attributed to the faster removal of reactive AGE-
peptides from the vascular space, since such substances are known
to react covalently with certain lipids [5, 15]. The exposure of
ApoB to circulating AGE results in its covalent AGE-, and
oxidative modification, in a manner that can be prevented by the
AGE-inhibitor aminoguanidine [5, 15]. The functional result of
this interaction could very well be decreased recognition and
clearance by the classic LDL receptor pathway, as was shown in
studies of mice over-expressing the human LDL receptor [5].
Delayed clearance due to advanced glycation could contribute to
the larger pool of circulating ApoB in these patients. In support of
this, plasma ApoB declined significantly in diabetic patients with
varying degrees of renal insufficiency in connection with a four
week course of oral aminoguanidine [5]. The present studies lend
further support to the expectation that the efficient elimination of
reactive AGE substances from human plasma, in this case by way
of high flux dialysis, can effect a substantial reduction of an
atherogenic substrate such as ApoB.
In conclusion, chronic high flux hemodialysis may provide an
improved form of treatment which can significantly enhance
AGE-peptide clearance, and thus reduce both serum ApoB and
glycated ApoB levels. This form of renal replacement may,
therefore, offer a valuable advantage over other forms of treat-
ment, as it may lead to an improvement of dyslipidemia and
atherosclerosis in hemodialysis patients.
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APPENDIX
Abbreviations used in this article are: Db/ESRD, patients with diabetes
and renal insufficiency; AGEs, advanced glycation endproducts; ApoB,
apolipoprotein B; LDL, low density lipoprotein; HDL, high density
lipoprotein; HF, high flux; LF, low flux; ESRD, end-stage renal disease;
4G9, anti-AGE monoclonal antibody.
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